Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Retained Earnings (2016 - 2025)

Amicus Therapeutics' Retained Earnings history spans 16 years, with the latest figure at -$2.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 0.99% year-over-year to -$2.8 billion, compared with a TTM value of -$2.8 billion through Dec 2025, down 0.99%, and an annual FY2025 reading of -$2.8 billion, down 0.99% over the prior year.
  • Retained Earnings for Q4 2025 was -$2.8 billion at Amicus Therapeutics, roughly flat from -$2.8 billion in the prior quarter.
  • The five-year high for Retained Earnings was -$2.1 billion in Q1 2021, with the low at -$2.8 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$2.6 billion, with a median of -$2.6 billion recorded in 2023.
  • Year-over-year, Retained Earnings decreased 15.18% in 2021 and then fell 0.51% in 2025.
  • Tracing FOLD's Retained Earnings over 5 years: stood at -$2.3 billion in 2021, then fell by 10.3% to -$2.5 billion in 2022, then fell by 5.99% to -$2.7 billion in 2023, then dropped by 2.09% to -$2.7 billion in 2024, then dropped by 0.99% to -$2.8 billion in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Retained Earnings are -$2.8 billion (Q4 2025), -$2.8 billion (Q3 2025), and -$2.8 billion (Q2 2025).